Integrating genetic screening into treatment planning for high risk MM

Treatment of multiple myeloma (MM) has improved greatly over the past few years; however, certain patients remain at high risk of rapid relapse, either because of general background traits, or because... Author: VJHemOnc Added: 07/05/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts

Related Links:

In this study, we used large-scale electronic health records data from multiple linked UK databases to address these evidence gaps.MethodsFor this population-based cohort study, we used linked primary care, hospital, and cancer registry data from the UK Clinical Practice Research Datalink to identify cohorts of survivors of the 20 most common cancers who were 18 years or older and alive 12 months after diagnosis and controls without history of cancer, matched for age, sex, and general practice. We compared risks for a range of cardiovascular disease outcomes using crude and adjusted Cox models. We fitted interactions to in...
Source: The Lancet - Category: General Medicine Source Type: research
We report a case of DIHS secondary to bortezomib.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research
Condition:   Multiple Myeloma in Relapse Intervention:   Drug: Clarithromycin Lenalidomide Dexamethasone (BiRd) Regimen Sponsor:   First Hospital of Jilin University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
All - oral regimen linked to higher satisfaction with treatment convenience in relapsed, refractory MM
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Oncology, Pharmacy, Journal, Source Type: news
Blood Cancer Journal, Published online: 20 August 2019; doi:10.1038/s41408-019-0227-3Inhibition of E-Selectin (GMI-1271) or E-selectin together with CXCR4 (GMI-1359) re-sensitizes multiple myeloma to therapy
Source: Blood Cancer Journal - Category: Hematology Authors: Source Type: research
Auer rods were first described in the cytoplasm of leukemia blasts by John Auer in 1906. Auer rods are commonly seen in myeloid progenitors, and serve as a diagnostic morphological feature of acute myeloid leukemia (AML) [1]. The differential diagnosis of hematopoietic neoplasms relies on the detection of cytoplasmic inclusions resembling Auer rods. Auer rod-like inclusions have been described in multiple myeloma [2], prolymphocytic leukemia (PLL) [3], B-cell acute lymphoblastic leukemia [4], chronic lymphocytic leukemia [4], splenic lymphoma [5] and nodal marginal zone lymphoma [6], which are quite distinct from the needl...
Source: Experimental Hematology - Category: Hematology Authors: Tags: Brief Communication Source Type: research
X-linked agammaglobulinemia (XLA), caused by a mutation in the Bruton’s tyrosine kinase (BTK) gene, is rarely reported in patients with recurrent hemophagocytic lymphohistiocytosis (HLH). This mutation leads to significantly reduced numbers of circulatory B cells and serum immunoglobulins in patients. Therefore, they exhibit repetitive bacterial infections since infancy, and immunoglobulin (Ig) replacement therapy is the primary treatment. HLH is a life-threatening condition with manifestations of nonremitting fever, hepatosplenomegaly, cytopenias, coagulopathy, lipid disorder, and multiple organ failure. It is cause...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
There is an increasing clinical interest in the measure and achievement of minimal residual disease (MRD) negativity in the bone marrow of Multiple Myeloma (MM) patients, as defined equally either by Multicolor Flow Cytometry (MFC) or by Next Generation Sequencing (NGS) technologies. At present, modern technologies allow to detect up to one on 104 or on 105 or even on 106 cells, depending on their throughput. MFC approaches, which have been progressively improved up to the so-called Next Generation Flow (NGF), and NGS, which proved clear advantages over ASO-PCR, can detect very low levels of residual disease in the BM. The...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Source: Annals of Hematology - Category: Hematology Source Type: research
Source: Annals of Hematology - Category: Hematology Source Type: research
More News: Cancer & Oncology | Genetics | Myeloma